At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
cediranib maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
In Brief
A Phase 2 clinical trial evaluating cediranib maleate and pemetrexed disodium for Recurrent Non-small Cell Lung Cancer. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
This phase II trial is studying how well giving AZD2171 together with pemetrexed disodium works in treating patients with relapsed non-small cell lung cancer. AZD2171 and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. AZD2171 may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving AZD2171 together with pemetrexed disodium may kill more tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedDec 2006
Primary CompletionJul 2013
Study CompletionMar 2014
TodayJul 2026
First PostedDec 13, 2006
Enrollment StartOct 1, 2006
Primary CompletionJul 1, 2013
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 19.6 years ago
Interventions
cediranib maleatedrug
pemetrexed disodiumdrug